Skip to main content
|
  1. Home
  2. Clinical Trials
  3. NRG-GI008/CIRCULATEUS

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Short Title: NRG-GI008/CIRCULATEUS


Enrollment Status: Recruiting

NCT #: NCT05174169

Specialty Area: Oncology

Condition Studied: Colon Cancer

Age Groups: Adult; Older Adult

Phase: II/III


Study Information

Summary / Purpose

To evaluate whether ctDNA-guided chemotherapy improves outcomes in patients with Stage III colon cancer.

Study Type: Interventional
Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:
  • Adults 18+ years of age
  • Diagnosed with resected Stage III colon cancer
  • Must be eligible for adjuvant (post-surgery) chemotherapy
  • No prior systemic therapy for colon cancer
  • Adequate organ function

What's Involved

Participation in the study will include:
  • ctDNA testing using the Signatera assay after surgery
  • Immediate or delayed chemotherapy which may include mFOLFOX6, CAPOX, or mFOLFIRINOX, based on ctDNA results
  • Regular blood draws to monitor ctDNA and response to treatment
  • CT scans to assess response to treatment

Principal Investigator

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT05174169

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

ER Wait Times

How are wait times calculated?

Our estimated ER wait times reflect the average time from check-in to being seen by a medical professional during triage, where patients are prioritized based on the severity of their condition.

Health & Wellness eNews
Sign Up